Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 300 versus OMNIPAQUE 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 300 versus OMNIPAQUE 9.
OMNIPAQUE 300 vs OMNIPAQUE 9
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing vascular and tissue opacification by increasing the density of blood vessels and organs.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/mL) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
Intravenous: 1-2 mL/kg (300 mg I/mL) for contrast-enhanced CT; intra-arterial: 5-80 mL per injection depending on procedure; maximum total dose 4 mL/kg.
Omnipaque 9 (iohexol 9 mg I/mL) is administered intravenously. For CT enhancement, typical adult dose is 50-100 mL (450-900 mg I) by slow IV injection.
None Documented
None Documented
The terminal elimination half-life of iohexol in patients with normal renal function (creatinine clearance > 90 mL/min) is approximately 1.5 to 2 hours. In patients with renal impairment, the half-life is significantly prolonged (up to 30 hours or more in severe renal failure), necessitating dose adjustment and careful monitoring.
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Omnipaque 300 (iohexol) is primarily eliminated unchanged by the kidneys via glomerular filtration. Renal excretion accounts for >95% of the administered dose within 24 hours in patients with normal renal function. Fecal excretion is negligible (<1%). Billiary excretion is minimal, with less than 0.1% recovered in bile or feces.
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent